Research Paper Volume 15, Issue 16 pp 8090—8112

Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma

class="figure-viewer-img"

Figure 4. Identification of HRD-related prognostic RNA. (A) Differential analysis based on HRD vs. non-HRD patients, 326 DEGs were obtained, of which 266 genes were expressed up in HRD patients, and 60 genes were expressed down in HRD patients. (B, C) After univariate Cox regression screening, 89 prognostic genes were obtained and analyzed by LASSO regularized dimensionality reduction and eliminated the covariance between variables, after which nine genes were obtained. (D) Multivariate Cox regression screening of independent prognostic genes, containing five genes, of which all were risk factors except for MS4A6A. (E) Cellular distribution of 109649 cells clustered into 3 unique subsets among all merged lung adenocarcinoma tissue samples. (F) FeaturePlot depicting the distribution of MS4A6A. (G) vlnPlot showing the expression levels of MS4A6A in different cell subsets. (H) Risk plots of multifactorial Cox regression with the distribution of risk score in the upper layer, the distribution range of survival information in the lower layer. (I) The expression characteristics of five genes in high and low-risk group. (J) KM curves of MS4A6A (log-rank test).